Skip to main content

Table 5 Mean urinary biomarkers of acute kidney injury as a ratio to urinary creatinine.

From: Assessment of hemodynamic efficacy and safety of 6% hydroxyethylstarch 130/0.4 vs. 0.9% NaCl fluid replacement in patients with severe sepsis: The CRYSTMAS study

 

Mean (SD)

Treatment group

Baseline

Until HDSa

Day 1

Day 2

Day 3

Day 4

Day 8b

Lastc

Alpha-1-microglobulin/urinary creatinine, g/mmol

HES 130/0.4

17.8 (21.0)

18.1 (14.8)

18.3 (16.0)

19.4 (20.3)

19.6 (20.5)

17.2 (14.4)

13.4 (14.9)

19.9 (22.7)

NaCI 0.9%

12.3 (12.9)

17.2 (18.0)

17.8 (17.1)

16.9 (15.0)

16.7 (14.9)

16.7 (13.8)

19.5 (23.9)

19.8 (23.3)

Beta-NAG/urinary creatinine, UI/mmol

HES 130/0.4

4.9 (6.6)

4.1 (3.5)

5.0 (3.8)

7.9 (12.8)

8.1 (13.6)

5.5 (4.6)

4.5 (3.0)

6.7 (10.0)

NaCI 0.9%

4.1 (4.7)

4.2 (3.5)

6.0 (9.1)

4.7 (4.2)

4.5 (4.4)

4.2 (3.3)

5.8 (5.0)

5.7 (5.5)

NGAL/urinary creatinine, μg/mmol

HES 130/0.4

283.0 (785.1)

352.8 (710.7)

229.9 (465.5)

325.9 (1,079.0)

432.9 (1458.2)

90.9 (203.4)

24.4 (71.5)

279.0 (884.8)

NaCI 0.9%

305.5 (833.9)

244.9 (452.4)

318.7 (644.8)

149.8 (303.2)

121.1 (306.1)

112.1 (373.7)

177.8 (551.5)

212.8 (604.8)

  1. aFirst measurement until HDS visit (i.e., data recorded at day of withdrawal were assigned to the study visit corresponding to the actual time point of measurement); bdata recorded on Day 8; clast available post-baseline measurement; HES, hydroxyethyl starch; NaCI, sodium chloride; NAG, N-acetyl-β-D-glucosaminidase; NGAL, neutrophil gelatinase associated lipocalin; SD, standard deviation; HDS, hemodynamic stabilization.